Frontlight ResearchEarly access
Taking people in United StatesNo phase
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Key facts
- Who runs it
- BeiGene
- Where
- Duarte, Glendale, Hattiesburg, Huntsville, Las Vegas, Mobile, and Rancho Mirage, United StatesSee the 7 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- People taking part
- 111 people, planned
- Started
- 3 Mar 2023
- Expected to end
- Dec 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Zanubrutinib
- Record updated
- 7 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Clinical and definitive histologic diagnosis of WM
- Measurable disease, as defined by a serum immunoglobulin M (IgM) level > 0.5 g/dL at the time of zanubrutinib initiation
- Started treatment with zanubrutinib, has been treated with zanubrutinib, or is planned to be prescribed zanubrutinib for the treatment of WM
- Bone marrow specimens with central MYD88 test results of:; Cohort 1: MYD88 L265P mutation; enrollment of TN participants will be stopped in each racial and ethnic participant group when the required numbers of participants in the group are met; Cohort 2: non-L265P MYD88 mutation(s) and MYD88WT
Who cannot take part
- Prior or concurrent active malignancy ≤ 2 years before the first dose of zanubrutinib, except for malignancies that, in the investigator's opinion, will not obscure the interpretation of safety or efficacy results
- Concurrent participation in another therapeutic clinical study while receiving zanubrutinib, although the participant may be eligible depending on the status of the interventional study after discussion with the Medical Monitor or designee on an individual basis
- Evidence of disease transformation before the first dose of zanubrutinib
- Evidence of other non-Hodgkin Lymphoma (NHL) subtypes
Where in United States
Also in 1 other country, 1 site
- City of Hope National Medical CenterDuarte, United StatesContact: Study DirectorTaking people
- Los Angeles Cancer Network (LACN)Glendale, United StatesContact: Study DirectorTaking people
- Hattiesburg Hematology and Oncology ClinicHattiesburg, United StatesContact: Study DirectorNo longer taking part
- Clearview Cancer InstituteHuntsville, United StatesContact: Study DirectorTaking people
- Comprehensive Cancer Centers of NevadaLas Vegas, United StatesContact: Study DirectorTaking people
- South Alabama Medical Science Foundation Mitchell Cancer InstituteMobile, United StatesContact: Study DirectorTaking people
- Eisenhower Medical Center, Lucy Curci Cancer CenterRancho Mirage, United StatesContact: Study DirectorTaking people
About the trial
What the trial wants to find out
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
The 2 groups in the trial
- Cohort 1: MYD88 L265P mutation
Arm A: Treatment-naïve (TN); Arm B: Relapsed/refractory (R/R)
Treatment: Zanubrutinib
- Cohort 2: Non-L265P MYD88 mutation(s) and MYD88 wildtype
Arm C: TN and R/R
Treatment: Zanubrutinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
- Record updated
- 7 August 2026